Table 4.
Summary statistics of simulated BMS‐823778 pharmacokinetic with the physiologically based pharmacokinetic model following oral doses (once every 3 days) at 10 mg to CYP2C19 PM Caucasians with different UGT1A4 genotypes
| Treatment Group | Study Day | Cmax (ng ml–1) (CV%) | AUC(τ) (ng h ml–1) (CV%) | Half‐life (h) (CV%) | AI |
|---|---|---|---|---|---|
| UGT1A4*1/*1 (normal activity) | 1 | 98.8 (3.2) | 3776.6 (285.3) | NA | |
| 60 | 237.7 (22.8) | 12276.1 (1577.8) | 135.6 (16.8) | 3.2 | |
| Polymorphic UGT1A4 (no activity) | 1 | 99.3 (13.8) | 4242.7 (229.1) | NA | |
| 60 | 366.7 (25.3) | 21 948 (1849.3) | 235.7 (19.6) | 5.2 |
NA, not applicable; AI, accumulation index
T‐half on day 1 was not calculated because of short terminal phase.